FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2906066719> ?p ?o ?g. }

• W2906066719 endingPage "684" @default.
• W2906066719 startingPage "678" @default.
• W2906066719 abstract "Objective Approximately 30–40% of rheumatoid arthritis (RA) patients who are initially started on low‐dose methotrexate (MTX) will not benefit from the treatment. To date, no reliable biomarkers of MTX inefficacy in RA have been identified. The aim of this study was to analyze whole blood samples from RA patients at 2 time points (pretreatment and 4 weeks following initiation of MTX), to identify gene expression biomarkers of the MTX response. Methods RA patients who were about to commence treatment with MTX were selected from the Rheumatoid Arthritis Medication Study. Using European League Against Rheumatism (EULAR) response criteria, 42 patients were categorized as good responders and 43 as nonresponders at 6 months following the initation of MTX treatment. Data on whole blood transcript expression were generated, and supervised machine learning methods were used to predict a EULAR nonresponse. Models in which transcript levels were included were compared to models in which clinical covariates alone (e.g., baseline disease activity, sex) were included. Gene network and ontology analysis was also performed. Results Based on the ratio of transcript values (i.e., the difference in log 2 ‐transformed expression values between 4 weeks of treatment and pretreatment), a highly predictive classifier of MTX nonresponse was developed using L2‐regularized logistic regression (mean ± SEM area under the receiver operating characteristic [ROC] curve [AUC] 0.78 ± 0.11). This classifier was superior to models that included clinical covariates (ROC AUC 0.63 ± 0.06). Pathway analysis of gene networks revealed significant overrepresentation of type I interferon signaling pathway genes in nonresponders at pretreatment ( P = 2.8 × 10 −25 ) and at 4 weeks after treatment initiation ( P = 4.9 × 10 −28 ). Conclusion Testing for changes in gene expression between pretreatment and 4 weeks post–treatment initiation may provide an early classifier of the MTX treatment response in RA patients who are unlikely to benefit from MTX over 6 months. Such patients should, therefore, have their treatment escalated more rapidly, which would thus potentially impact treatment pathways. These findings emphasize the importance of a role for early treatment biomarker monitoring in RA patients started on MTX." @default.
• W2906066719 created "2019-01-01" @default.
• W2906066719 creator A5000205562 @default.
• W2906066719 creator A5001906034 @default.
• W2906066719 creator A5022863158 @default.
• W2906066719 creator A5036981821 @default.
• W2906066719 creator A5038688193 @default.
• W2906066719 creator A5043222381 @default.
• W2906066719 creator A5086012146 @default.
• W2906066719 creator A5088575178 @default.
• W2906066719 date "2019-03-19" @default.
• W2906066719 modified "2023-10-18" @default.
• W2906066719 title "Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis" @default.
• W2906066719 cites W1492996609 @default.
• W2906066719 cites W1634658554 @default.
• W2906066719 cites W1770946500 @default.
• W2906066719 cites W1811521558 @default.
• W2906066719 cites W1847132790 @default.
• W2906066719 cites W1892496998 @default.
• W2906066719 cites W1966327575 @default.
• W2906066719 cites W198452255 @default.
• W2906066719 cites W1985213868 @default.
• W2906066719 cites W2000177767 @default.
• W2906066719 cites W2074062119 @default.
• W2906066719 cites W2081877046 @default.
• W2906066719 cites W2110177517 @default.
• W2906066719 cites W2113435829 @default.
• W2906066719 cites W2122295644 @default.
• W2906066719 cites W2131262676 @default.
• W2906066719 cites W2133103918 @default.
• W2906066719 cites W2138255346 @default.
• W2906066719 cites W2138282709 @default.
• W2906066719 cites W2144679801 @default.
• W2906066719 cites W2146378328 @default.
• W2906066719 cites W2146512944 @default.
• W2906066719 cites W2151845001 @default.
• W2906066719 cites W2156049013 @default.
• W2906066719 cites W2156449368 @default.
• W2906066719 cites W2160208009 @default.
• W2906066719 cites W2164305413 @default.
• W2906066719 cites W2168546553 @default.
• W2906066719 cites W2315070091 @default.
• W2906066719 cites W2577490495 @default.
• W2906066719 cites W2600342248 @default.
• W2906066719 cites W2783251447 @default.
• W2906066719 cites W3184260731 @default.
• W2906066719 cites W45832520 @default.
• W2906066719 doi "https://doi.org/10.1002/art.40810" @default.
• W2906066719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30615300" @default.
• W2906066719 hasPublicationYear "2019" @default.
• W2906066719 type Work @default.
• W2906066719 sameAs 2906066719 @default.
• W2906066719 citedByCount "43" @default.
• W2906066719 countsByYear W29060667192019 @default.
• W2906066719 countsByYear W29060667192020 @default.
• W2906066719 countsByYear W29060667192021 @default.
• W2906066719 countsByYear W29060667192022 @default.
• W2906066719 countsByYear W29060667192023 @default.
• W2906066719 crossrefType "journal-article" @default.
• W2906066719 hasAuthorship W2906066719A5000205562 @default.
• W2906066719 hasAuthorship W2906066719A5001906034 @default.
• W2906066719 hasAuthorship W2906066719A5022863158 @default.
• W2906066719 hasAuthorship W2906066719A5036981821 @default.
• W2906066719 hasAuthorship W2906066719A5038688193 @default.
• W2906066719 hasAuthorship W2906066719A5043222381 @default.
• W2906066719 hasAuthorship W2906066719A5086012146 @default.
• W2906066719 hasAuthorship W2906066719A5088575178 @default.
• W2906066719 hasBestOaLocation W29060667191 @default.
• W2906066719 hasConcept C119043178 @default.
• W2906066719 hasConcept C119857082 @default.
• W2906066719 hasConcept C126322002 @default.
• W2906066719 hasConcept C143998085 @default.
• W2906066719 hasConcept C151956035 @default.
• W2906066719 hasConcept C2777077863 @default.
• W2906066719 hasConcept C2777489490 @default.
• W2906066719 hasConcept C2777575956 @default.
• W2906066719 hasConcept C2781059491 @default.
• W2906066719 hasConcept C41008148 @default.
• W2906066719 hasConcept C58471807 @default.
• W2906066719 hasConcept C71924100 @default.
• W2906066719 hasConceptScore W2906066719C119043178 @default.
• W2906066719 hasConceptScore W2906066719C119857082 @default.
• W2906066719 hasConceptScore W2906066719C126322002 @default.
• W2906066719 hasConceptScore W2906066719C143998085 @default.
• W2906066719 hasConceptScore W2906066719C151956035 @default.
• W2906066719 hasConceptScore W2906066719C2777077863 @default.
• W2906066719 hasConceptScore W2906066719C2777489490 @default.
• W2906066719 hasConceptScore W2906066719C2777575956 @default.
• W2906066719 hasConceptScore W2906066719C2781059491 @default.
• W2906066719 hasConceptScore W2906066719C41008148 @default.
• W2906066719 hasConceptScore W2906066719C58471807 @default.
• W2906066719 hasConceptScore W2906066719C71924100 @default.
• W2906066719 hasFunder F4320307765 @default.
• W2906066719 hasFunder F4320320045 @default.
• W2906066719 hasFunder F4320334626 @default.
• W2906066719 hasIssue "5" @default.
• W2906066719 hasLocation W29060667191 @default.
• W2906066719 hasLocation W29060667192 @default.

• next